Medpointe Pharmaceuticals Medpointe Healthcare
As of the edition of 20 October 2026, Medpointe Pharmaceuticals Medpointe Healthcare runs 9 drugs, 9 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 9 |
| Total | 9 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Niacin | none listed | 0 |
| Bepridil | none listed | 0 |
| Cryptenamine acetates | none listed | 0 |
| Cryptenamine tannates | none listed | 0 |
| Hexafluorenium | none listed | 0 |
| Mebutamate | none listed | 0 |
| Meprobamate | none listed | 3 |
| Methyclothiazide | none listed | 0 |
| Veratrum viride root | none listed | 0 |
A route B row is one company at one target.